Boehringer Ingelheim Corporate News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Carmelina
Boehringer Ingelheim and Lilly present full results of Trajenta ®’s CARMELINA® cardiovascular outcome trial Trajenta ® demonstrated a similar long-term cardiovascular and kidney safety profile compared to placebo in adults with type 2 diabetes1 The results of CARMELINA ® were presented at the 54th EASD Annual Meeting today (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 25, 2018 Category: Research Source Type: news

Real-world study reports effects of Spiolto Respimat
Large European real-world study reports effects of Spiolto ® Respimat® for people living with COPD in daily clinical practice1OTIVACTO study reported improvements in both physical functioning and general condition in people living with COPD receiving Spiolto ®(tiotropium/olodaterol) Respimat® therapy14 out of 5 patients reported high satisfaction with their Respimat ® inhaler and tiotropium/olodaterol treatment overall1Data presented at European Respiratory Society International Congress 20181 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 16, 2018 Category: Research Source Type: news

INSTAGE data for nintedanib in advanced IPF published
Clinical trial data for nintedanib in patients with advanced IPF published   INSTAGE ® trial results published in the New England Journal of Medicine1Trial provides clinical data on patients with IPF and severe impairment in gas exchange usually excluded from clinical trials1Efficacy and safety profile of nintedanib in patients with advanced IPF was consistent with that observed in patients with less advanced disease in earlier trials1,2,3,4Sildenafil plus nintedanib did not provide significant benefit   versus nintedanib alone1  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 16, 2018 Category: Research Source Type: news

INPULSIS-ON shows ofev slows progression of IPF
New study results provide evidence that Ofev ® (nintedanib) slows progression of IPF beyond four years with consistent safetyINPULSIS ®-ON study indicates safety and efficacy of Ofev®(nintedanib) are maintained over the long term and consistent with prior findings from INPULSIS® trials1Results from INPULSIS ®-ON, the open-label extension from the two INPULSIS® Phase III trials, published in Lancet Respiratory Medicine1  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 15, 2018 Category: Research Source Type: news

Boehringer Ingelheim acquires all ViraTherapeutics shares
Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies  Boehringer Ingelheim exercises its option to acquire all shares of oncolytic virus company ViraTherapeuticsViraTherapeutics will operate in Innsbruck, Austria as a distinct unit of Boehringer Ingelheim ’s Discovery Research organization, maintaining its innovative biotech heritage and close connections to the Medical University of Innsbruck and the regional scientific communityAcquisition strengthens Boehringer Ingelheim ’s commitment to research and development of viral-based immuno-oncology tre...
Source: Boehringer Ingelheim Corporate News - September 12, 2018 Category: Research Source Type: news

Cyltezo-Phase III -in Psoriasis
Biosimilar Cyltezo ® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasisData show that Cyltezo © (adalimumab- adbm) and Humira®* have similar efficacy, safety and immunogenicity in people with moderate-to-severe chronic plaque psoriasis1At week 16, the study met the primary endpoint, demonstrating clinical equivalence to Humira ®1Data will be presented at the European Association of Dermatology and Venereology Annual Meeting (EADV 2018) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 12, 2018 Category: Research Source Type: news

Changes to the Leadership of Boehringer Ingelheim
’s Corporate Department Medicine (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 10, 2018 Category: Research Source Type: news

The first liquid solution for hypertension in cats
Boehringer Ingelheim launches the first liquid solution for hypertension in catsSemintra ® 10 mg/ml Oral Solution now licenced to treat and control feline hypertensionA new and easy-to-give solution for a common problem in catsBoehringer Ingelheim continues to set new standards of care to strengthen its commitment to animal welfare (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 4, 2018 Category: Research Source Type: news

New Partnership to Develop Novel Treatment Approaches Against Infectious Diseases
Boehringer Ingelheim and Tsinghua University Team up to Develop Novel Treatment Approaches that Rally the Immune System Against Infectious DiseasesThe new collaboration aims to develop novel breakthrough therapy approaches applying principles of immune modulation to infectious diseases  Immuno-infection is a new focus area of Boehringer Ingelheim ’s Research Beyond Borders (RBB) department, which explores emerging science and technology beyond the company’s core areas of focusBoehringer Ingelheim and Tsinghua University will establish a Joint Research Center for Immuno-Infection for new therapy concept exploration as ...
Source: Boehringer Ingelheim Corporate News - September 3, 2018 Category: Research Source Type: news

Biologicals_BeiGene_NDA_China
Boehringer Ingelheim Biopharmaceuticals China supports BeiGene in its China NDA submission of anti-PD-1 antibody, tislelizumabFirst biologic manufactured by Boehringer Ingelheim BioChina accepted for New Drug Application reviewImportant milestone for Boehringer Ingelheims ’ collaboration partner BeiGene in immuno-oncologyBoehringer Ingelheim BioChina is proud to support BeiGene in serving patients worldwide with this important medicine   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 3, 2018 Category: Research Source Type: news

new_solids_tablet_ launch_facility_ingelheim
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 21, 2018 Category: Research Source Type: news

Canbridge_contract_bio_manufacturing
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 20, 2018 Category: Research Source Type: news

New data at ESC supports Pradaxa safety profile
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 16, 2018 Category: Research Source Type: news

GioTag
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 8, 2018 Category: Research Source Type: news

New Partnership to Develop Gene Therapy for Cystic Fibrosis
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 6, 2018 Category: Research Source Type: news